Substance / Medication

Tissue plasminogen activator

Overview

Active Ingredient
alteplase
RxNorm CUI
8410

Indications

® ® CathfloActivase(Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.

Labeler: Genentech, Inc.Updated: 2026-01-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

DESCRIPTION Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation (see).

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Dual antiplatelet therapy versus intravenous tissue plasminogen activator with acute minor ischemic stroke: A systematic review and meta-analysis of safety and efficacy.
Abbas Abdallah, Hamad Abdullah Ashraf, El Din Moawad Mostafa Hossam et al. · J Stroke Cerebrovasc Dis · 2024
PMID: 38561167Meta-Analysis
Does the administration of sonothrombolysis along with tissue plasminogen activator improve outcomes in acute ischemic stroke? A systematic review and meta-analysis.
Zafar Marium, Memon Roha Saeed, Mussa Muhammad et al. · J Thromb Thrombolysis · 2019
PMID: 31214876Meta-Analysis
Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis.
You Shoujiang, Saxena Anubhav, Wang Xia et al. · Stroke Vasc Neurol · 2018
PMID: 29600004Meta-AnalysisFull text (PMC)
Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review.
Wang Xia, You Shoujiang, Sato Shoichiro et al. · Stroke Vasc Neurol · 2018
PMID: 29600005Meta-AnalysisFull text (PMC)
Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Cheng Ji-Wei, Zhang Xiao-Jing, Cheng Li-Shan et al. · J Stroke Cerebrovasc Dis · 2018
PMID: 29111341Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tissue plasminogen activator (substance)
SNOMED CT
37411004
UMLS CUI
C0032143
RxNorm CUI
8410
Labeler
Genentech, Inc.

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.